Financial reports
ARS
2023 FY
Annual report to shareholders
10 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
ARS
2022 FY
Annual report to shareholders
17 Jul 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K/A
2022 FY
Annual report (amended)
24 Apr 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
Current reports
8-K
Available in the U.S. by Prescription for Patients Aged Two Years and Older
13 Mar 24
8-K
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28 Feb 24
8-K
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD
21 Feb 24
8-K
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock
9 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5 Jan 24
8-K
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
19 Dec 23
8-K
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
7 Dec 23
8-K
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
8 Nov 23
8-K
New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio
3 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
5 Jan 24
424B5
Prospectus supplement for primary offering
4 Jan 24
S-8
Registration of securities for employees
8 Dec 23
S-8
Registration of securities for employees
8 Dec 23
S-3ASR
Automatic shelf registration
8 Sep 23
424B3
Prospectus supplement
31 Jul 20
S-3
Shelf registration
23 Jul 20
424B5
Prospectus supplement for primary offering
11 Sep 19
S-8
Registration of securities for employees
29 Jun 18
424B5
Prospectus supplement for primary offering
28 Nov 17
Proxies
DEF 14A
Definitive proxy
10 Apr 24
DEF 14A
Definitive proxy
12 Jul 23
DEFA14A
Additional proxy soliciting materials
7 Sep 22
DEF 14A
Definitive proxy
5 Aug 22
DEF 14A
Definitive proxy
26 Oct 21
DEFA14A
Additional proxy soliciting materials
3 Aug 20
DEF 14A
Definitive proxy
7 Jul 20
PRE 14A
Preliminary proxy
18 Jun 20
DEF 14A
Definitive proxy
18 Apr 19
DEF 14A
Definitive proxy
17 Apr 18
Other
EFFECT
Notice of effectiveness
3 Aug 20
CORRESP
Correspondence with SEC
30 Jul 20
UPLOAD
Letter from SEC
30 Jul 20
UPLOAD
Letter from SEC
13 Dec 19
CORRESP
Correspondence with SEC
6 Dec 19
CORRESP
Correspondence with SEC
12 Nov 19
UPLOAD
Letter from SEC
8 Nov 19
CT ORDER
Confidential treatment order
27 Feb 19
CT ORDER
Confidential treatment order
28 Sep 18
EFFECT
Notice of effectiveness
26 Jul 17
Ownership
4
David S Tierney
10 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
4
Brian Elsbernd
28 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
4
Carmen Jeffrey Del
16 Feb 24
4
Richard J Daly
16 Feb 24
4
DONALD A DENKHAUS
16 Feb 24
4
David S Tierney
16 Feb 24
4
Charles B O'Keeffe
16 Feb 24
4
Steve Miller
16 Feb 24